Welcome to our dedicated page for Rein Therapeutics news (Ticker: RNTX), a resource for investors and traders seeking the latest updates and insights on Rein Therapeutics stock.
Rein Therapeutics, Inc. (NASDAQ: RNTX) is a clinical-stage biopharmaceutical company focused on first-in-class therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications. The RNTX news feed highlights company announcements, scientific publications, regulatory updates, clinical milestones, and financing developments that shape the outlook for its pipeline.
Investors and observers can follow detailed updates on LTI-03, Rein’s lead Caveolin-1–related peptide candidate for IPF. Recent news has covered initiation and progress of the global Phase 2 RENEW trial, including first patient dosing, regulatory authorizations from the U.K. MHRA and the European Medicines Agency for sites in the United Kingdom, Germany, and Poland, and the U.S. Food and Drug Administration’s decision to lift a full clinical hold on the U.S. portion of the study.
The news stream also features translational and clinical science, such as peer-reviewed and preprint publications describing LTI-03’s anti-fibrotic activity in ex vivo lung tissue from IPF patients and inhaled dose-escalation studies assessing safety, pharmacokinetics, and biomarker changes. These reports discuss reductions in fibrosis-associated biomarkers, effects on multiple scarring pathways, and preservation of alveolar epithelial type II progenitor cells.
Additional coverage includes updates on LTI-01 for loculated pleural effusions, corporate and governance events such as annual meeting notices and adjournments, and capital markets activity, including pre-paid advance and standby equity purchase agreements and their subsequent termination. By reviewing RNTX news, readers can track how Rein Therapeutics communicates clinical progress, regulatory interactions, and strategic financing decisions that influence its development programs.
Rein Therapeutics (NASDAQ: RNTX) has reported its Q4 and full-year 2024 financial results, highlighting progress in its lead asset LTI-03 for idiopathic pulmonary fibrosis (IPF). The company announced positive topline results from Phase 1b Cohort 2 trial, with four biomarkers achieving statistical significance and five showing dose-dependent effects.
Financial highlights include:
- Cash position of $12.9M as of December 31, 2024 (down from $17.3M in 2023)
- Q4 2024 net loss of $41.0M, including $37.0M non-cash impairment charge
- Full-year R&D expenses increased to $14.2M from $4.0M in 2023
- G&A expenses rose to $13.9M from $11.4M in 2023
The company plans to initiate a Phase 2 trial for LTI-03 in IPF during first half of 2025, subject to funding. Additionally, Rein entered an exclusive option agreement with Advancium Health Network for ALRN-6924 and completed its rebranding from Aileron Therapeutics in January 2025.
Aileron Therapeutics announced its rebranding to Rein Therapeutics, reflecting its focus on developing therapies for orphan pulmonary and fibrosis indications. The company's stock will trade under the new symbol RNTX starting January 13, 2025.
The company reported positive topline data from Cohort 2 of its Phase 1b trial for LTI-03 in November 2024, showing statistical significance in four biomarkers and dose dependence in five markers for idiopathic pulmonary fibrosis (IPF) treatment. The high-dose LTI-03 (5 mg BID) demonstrated a favorable safety profile.
In 2024, Brian Windsor was appointed CEO, and the company raised $17.7 million through a stock offering. For 2025, Rein plans to initiate a Phase 2 trial for LTI-03 in IPF treatment. The company also has LTI-01, a Phase 2b-ready asset for loculated pleural effusions, which has received Orphan Drug and Fast Track Designations.